Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Value-Added Medicines

Set Alert for Value-Added Medicines

Teva Gets Investment From Royalty On Olanzapine LAI

Teva has announced a new investment from Royalty Pharma in its long-acting injectable formulation of olanzapine that is being developed for the US market with partner MedinCell.

Deals Value-Added Medicines

European Opportunities Loom For Value Added Medicines

Upcoming opportunities facilitated by the EU’s pharma legislation review were highlighted at Medicines for Europe’s fifth annual value added medicines conference, held in Brussels in early November. However, enthusiasm was tempered with acknowledgements that the European sector current lags behind the US and needs further reform to attract investment.

Value-Added Medicines Europe

Burt Succeeds Narayan As European Value Added Medicines Chair

At Medicines for Europe’s fifth annual value added medicines conference, the association announced that Pharmanovia CEO James Burt would take over as chair of its value added medicines sector group from Viatris executive Arun Narayan.

Executive Changes Leadership

UK’s ‘Pioneering’ Medicines Repurposing Program Delivers First License

Now that the first license for a drug has been obtained in partnership with the program, work will begin to ensure other companies that make the product adopt the new licensed indication.

Value-Added Medicines United Kingdom

What’s Next? Five Things To Look Out For In November

Generics Bulletin previews the most notable and anticipated events for November 2023

Biosimilars Generic Drugs

Sandoz Takes Treble Honors At GGB Awards 2023

Sandoz has triumphed at the Global Generics & Biosimilars Awards 2023, taking home three prizes while Samsung Bioepis also walked away with multiple trophies at our prizegiving ceremony in Barcelona.

Generic Drugs Biosimilars

Hyloris And Hikma Get Maxigesic IV Approval In US

Hyloris has announced US FDA approval for its Maxigesic IV innovative paracetamol/ibuprofen solution for infusion. The product is expected to launch in the US in early 2024 via marketing partner Hikma, under the name Combogesic IV.

Approvals Value-Added Medicines

One Week Remains Until Industry Awards

Entrants now have just one week until they discover who will be named as the winners of the Global Generics & Biosimilars Awards 2023, which are being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona.

Generic Drugs Biosimilars

What’s Next? Five Things To Look Out For In October

Generics Bulletin previews the most notable and anticipated events for October 2023.

Biosimilars Generic Drugs

Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma

In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.

M & A Deals

Shortlist Revealed Ahead Of October Awards

Ahead of the Global Generics & Biosimilars Awards, which are this year being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona, we reveal our final shortlist of entrants across all 14 categories.

Generic Drugs Biosimilars

Rani Takes Next Step As Oral Ustekinumab Biosimilar Enters The Clinic

As biosimilars to Stelara (ustekinumab) continue to advance in global markets, Rani Therapeutics has made progress for its proposed RT-111 orally administered ustekinumab biosimilar.

Biosimilars Value-Added Medicines

Not In 2023 After All? FDA Turns Down Approval For Coherus’ On-Body Pegfilgrastim

Coherus BioSciences says that it will work closely with the US Food and Drug Administration and the unnamed third-party filler to obtain approval for its proposed version of Neulasta Onpro on-body injector “as quickly as possible.”

Biosimilars Value-Added Medicines

Judges Weigh Record Entries Ahead Of October’s GGB Awards

Now in its tenth year, the Global Generics & Biosimilars Awards has received a record-breaking number of entries in 2023. Judges are now evaluating the nominees ahead of our awards ceremony on Wednesday 25 October at the Hotel Porta Fira in Barcelona.

Generic Drugs Biosimilars

Teva’s Francis: I Looked At All The Sexy Stuff And Overlooked Olanzapine

After launching the Uzedy long-acting formulation of risperidone in partnership with MedinCell earlier this year, Teva has stressed the “really exciting” product profile of another long-acting antipsychotic from the partnership, olanzapine, while discussing how it will avoid the safety pitfalls of legacy products in the space.

Value-Added Medicines Strategy

What’s Next? Five Things To Look Out For In September

Generics Bulletin previews the most notable and anticipated events for September 2023.

Biosimilars Generic Drugs
See All
UsernamePublicRestriction

Register